E-viri
PDF
Recenzirano
Odprti dostop
-
Ridker, Paul M; Everett, Brendan M; Pradhan, Aruna; MacFadyen, Jean G; Solomon, Daniel H; Zaharris, Elaine; Mam, Virak; Hasan, Ahmed; Rosenberg, Yves; Iturriaga, Erin; Gupta, Milan; Tsigoulis, Michelle; Verma, Subodh; Clearfield, Michael; Libby, Peter; Goldhaber, Samuel Z; Seagle, Roger; Ofori, Cyril; Saklayen, Mohammad; Butman, Samuel; Singh, Narendra; Le May, Michel; Bertrand, Olivier; Johnston, James; Paynter, Nina P; Glynn, Robert J
The New England journal of medicine, 02/2019, Letnik: 380, Številka: 8Journal Article
Patients with coronary artery disease were randomly assigned to either methotrexate (15 to 20 mg weekly) or placebo. At a median of 2.3 years, there was no difference between the two groups in the rate of myocardial infarction, stroke, or cardiovascular death.
